1.1.4 Irritable bowel syndrome

Linaclotide may be considered for use in adults with moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) who fulfill both of the following criteria:

1. They have not responded adequately to or cannot tolerate all other suitable treatment options including optimal or maximum tolerated doses of laxatives from different classes.
2. They have had constipation for at least 12 months.

Patients must have a scheduled review after 4 weeks of initiating treatment and linaclotide should be discontinued where symptoms have not improved.

Linaclotide should form part of a multifaceted approach to the management of IBS that emphasises the importance of self-help, general lifestyle, physical activity and diet.

Linaclotide for irritable bowel syndrome with constipation PRGC Jul 2019 Click Here